Early detection of cancer, a disease that continues to represent a significant global health burden, remains one of the most critical factors in improving survival outcomes. In response, healthcare systems are increasingly focusing on strengthening diagnostic pathways and adopting advanced clinical tools to support more efficient evaluation and management of patients at risk. Against this backdrop, the digital health market in Australia is expected to grow at a compound annual growth rate (CAGR) of 10% through 2035, forecasts GlobalData, a leading intelligence and productivity platform.
GlobalData’s analysis reveals that Australia accounted for 2% of the Asia-Pacific (APAC) digital health market in 2025. Despite this relatively small share, the country’s contribution is expected to expand as healthcare providers are adopting emerging technologies alongside the existing digital solutions, supporting the growth of the Australian digital health sector.
Optellum has recently received regulatory clearance from the Therapeutic Goods Administration (TGA) in Australia for its AI-enabled Virtual Nodule Clinic, a digital health platform developed to support clinicians in assessing pulmonary nodules and aiding in the early detection of possible lung cancer. This authorization allows healthcare providers across Australia to integrate the software-based clinical decision support tool into their routine diagnostic and patient management processes.
Shamreen Parween, Medical Devices Analyst at GlobalData, comments: “The incidence of cancer in Australia is increasing due to a range of contributing factors, highlighting the growing need for effective and timely diagnostic approaches alongside the existing healthcare infrastructure. In this context, initiatives by the Australian Government to promote the adoption of accessible and cost-effective medical technologies may play an important role in improving treatment outcomes and enhancing survival rates among patients.”
Optellum has already received FDA approval and CE marking in European countries and has now secured TGA approval in Australia. This approval supports an artificial intelligence (AI) model that helps predict whether lung cancer is malignant. The software, which is built into the system, reviews chest CT images where lung nodules have been detected. Based on the calculated result, the experts determine the next steps for further treatment. Such assessments may contribute to earlier identification and management of lung cancer, potentially supporting improved outcomes for patients.
Parween concludes: “The development of digital healthcare and the increasing integration of technology-driven solutions across clinical environments are likely to support improvements in disease diagnosis and treatment, while gradually strengthening Australia’s position within the broader Asia-Pacific digital health market.”
Notes
Quotes provided by Shamreen Parween, Medical Devices Analyst at GlobalData
About GlobalData
GlobalData Plc (LSE:DATA) operates an intelligence platform that empowers leaders to act decisively in a world of complexity and change. By uniting proprietary data, human expertise, and purpose-built AI into a single, connected platform, we help organizations see what is coming, move faster, and lead with confidence. Our solutions are used by over 5,000 organizations across the world’s largest industries, providing tailored intelligence that supports strategic planning, innovation, risk management, and sustainable growth.